ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

Also called NCT07187713

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Ace Cells Lab Limited (from the registry)
Registry
  • NCT NCT07187713
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07187713. Allocation not applicable; no masking; primary purpose treatment. Start 2025-09-20 (anticipated); primary completion 2026-08-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases
Acronym
ACE Reno
Condition
Hypertensive Nephropathy
Condition
Auto Immune Disorders
Condition
Chronc Kidney Disease Stage 5
Condition
Chronic Kidney Disease (Stage 3-4)
Condition
Chronic Kidney Disease (Stages 4 and 5)
Condition
Microalbuminuria
Condition
Diabetic Nephropathies
Intervention (Drug)
ACE Reno
Lead sponsor
Ace Cells Lab Limited (class: industry)

Record details

Record id
cardio:ct-nct07187713
Content hash
a94b850b67239c0194df4544e264a4a9bdaecc49eb542ce13d7eca5006efd356